Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
तुलना करने के लिए मीट्रिक्स | HEMO | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधHEMOपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −2.4x | −3.4x | −0.6x | |
PEG अनुपात | −0.07 | −0.02 | 0.00 | |
क़ीमत/बुक | 4.0x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 12.4x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 180.1% | 54.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.0% | 7.7% | अनलॉक करें |